Physician profile
John W Head
NPI 1750393690
$28,312.22
in general payments reported to CMS, 2019-2025
20 companies · $7,249 in 2025
The $7,249 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,019 · 2020: $2,860 · 2021: $3,189 · 2022: $2,612 · 2023: $3,535 · 2024: $4,849 · 2025: $7,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,333.29 |
| Education | $299.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,244.85 | 2021-2025 | |
| Lundbeck LLC | $4,083.73 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $3,720.04 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $2,909.81 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $2,266.91 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Indivior INC. | $1,906.08 | 2019-2025 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $1,569.52 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $1,524.93 | 2019-2025 | Ingrezza |
| Allergan, INC. | $1,430.77 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $1,033.97 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $914.50 | 2019-2023 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $759.58 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $607.42 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Takeda Pharmaceuticals U.S.A., INC. | $605.32 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $450.34 | 2020-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $186.01 | 2023-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $34.71 | 2022-2023 | Quviviq |
| Braeburn INC. | $31.64 | 2024 | Brixadi |
| Luye Pharma (USA) Ltd. | $20.72 | 2025 | Erzofri Extended-Release |
| Acadia Pharmaceuticals INC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.